Global Blau Syndrome Market is expected to grow with the CAGR of 11.9% in the forecast period of 2020 to 2027. The years considered for study are as mentioned below:

Access full Report @ https://www.databridgemarketresearch.com/reports/global-blau-syndrome-market

Global Blau syndrome market is a highly consolidated market, which includes specific number of key players. The market has witnessed increased strategic developments owing to favourable market scenario.   

The major players dealing in global Blau syndrome market are introducing strong range of products provider along with launching new products and adopting strategic initiative such as acquisition, agreement, business expansion, award and recognition into the market. This helped companies to maximize the sales with enhanced product portfolio.

For instance:

• In October 2018, Amgen Inc., Amgen launched AMGEVITA, (an adalimumab) in different markets across European region. This product launch helped the company to enhance its product sale and to improve its research capabilities.

Novartis AG is the dominating player in global Blau syndrome market. The other key players existing in the market includes Pfizer Inc., AbbVie Inc., Amgen Inc., Janssen Pharmaceuticals, Inc.(A Subsidiary of Johnson & Johnson Services Inc.), Mylan N.V., Hikma Pharmaceuticals PLC, Teva Pharmaceutical U.S.A Inc. (a subsidiary of Teva Pharmaceutical Industries Ltd.), Fulgent Genetics Inc., Invitae Corporation, Swedish Orphan Biovitrum AB, Alkem Labs., Accord Healthcare, F. Hoffmann-La Roche Ltd, Zydus Pharmaceuticals (USA) Inc. (a subsidiary of Zydus cadila), Amneal Pharmaceuticals LLC, Salix Pharmaceuticals (a subsidiary of Bausch Health Companies Inc.), Centogene AG and Oncodesign among others.

Novartis AG

Novartis AG headquarter is in Basel, Switzerland, mainly focuses on innovating new solutions for various health care challenges. The company has two business segments including Innovative Medicines, Sandoz, in these Innovative Medicines is the market focussed segment. The company has wide product portfolio such as Cancer, Cardiovascular, Renal & Metabolism, Immunology & Dermatology, Ophthalmology, Neuroscience, Respiratory, in which Immunology & Dermatology is the market focused category.

• In September 2016, Novartis received FDA approval for Ilaris (canakinumab) for treatment of Periodic Fever conditions associated with rare syndromes. As episodic fever is one of the symptom associated with Blau syndrome, this product approval helped the company to enhance its product portfolio for treatment of Blau syndrome.

The company has wide presence across Americas, Asia-Pacific, Europe/Middle East /Africa. The company also has various subsidiary companies such as Novartis Argentina S.A., Buenos Aires(Argentina), Novartis Australia Pty Ltd, Macquarie Park, NSW(Australia), Novartis Austria GmbH, Vienna(Austria), Novartis Pharma NV, Vilvoorde(Belgium), Sandoz (China) Pharmaceutical (China) among others.

Amgen Inc.

Amgen Inc. headquartered in California, U.S. was founded in 1980. The company focuses on the use of science and technology in search of therapies in order to improve the lives of those who suffer from serious diseases. The company has wide product portfolio including AMJEVITA, Aimovig, AVSOLA, Enbrel, EPOGEN, KANJINTI, Neulasta, Vectibix, XGEVA among others in which AMJEVITA, AVSOLA, Enbrel are the market focused categories.

• In December 2019, Amgen Inc., received FDA approval for AVSOLA (infliximab). This product is used for the treatment of rheumatoid arthritis among others. Rheumatoid arthritis is a common symptom associated with Blau syndrome. This product approval helped the company to enhance its product portfolio for Blau syndrome treatment.

The company has wide presence across Americas, Europe, Asia. The company also has various subsidiary companies such as Amgen Canada Inc.(Ontario), Amgen (Europe) GmbH(Switzerland), Amgen Manufacturing, Limited(Bermuda), Amgen Rockville, Inc.(Delaware), ATL Holdings Limited(Bermuda) among others.

Pfizer Inc.

Pfizer Inc. headquartered in New York, U.S. was founded in 1849. The company focuses on providing standard for quality, safety and value in the discovery, development and manufacture of health care products, including innovative medicines and vaccines. The company is engaged in providing wide range of product categories such as ACCUPRIL, ALTACE, AZITHROMYCIN,ENBREL (ETANERCEPT) IBRANCE, INFLECTRA, INSPRA, METHOTREXATE, among others in which AZITHROMYCIN, ENBREL (ETANERCEPT), INFLECTRA, METHOTREXATE are the market focused product categories.

• In September 2015, Pfizer Inc. completed acquisition of Hospira, which is a leading provider of biosimilar and injectable drugs. Some biosimilar drugs are used for the treatment of Blau syndrome such as Enbrel (etanercept) among others. This acquisition has helped the company to expand its global market of biosimilar.

The company is present in Europe, Middle East & Africa, Americas, Asia-Pacific. The company has several owned subsidiaries involving Pfizer Animal Health B.V. (Netherlands), Pfizer Asia International B.V. (Netherlands), Pfizer Australia Superannuation Pty Ltd (Australia), Pfizer Dominicana, S.A. (Dominican Republic), Pfizer Egypt S.A.E. (Egypt) among others.